- Raised $38M funding round, Aug 2017
- Raised $8.5M funding round, Nov 2013
About
Eloxx Pharmaceuticals focuses on the discovery, development, and commercialization of compounds for the treatment of rare genetic diseases including cystic fibrosis, Duchenne muscular dystrophy, Usher syndrome, ataxia-telangiectasia, beta thalassemia, and Tay-Sachs Hurler syndrome. Its platform technologies are uniquely positioned to transform genetic diseases by correcting two defects, nonsense mutations implicated in many rare diseases and ribosomal mutations driving cancer.
The companys approach allows it to move rapidly from a target drug-discovery program to clinical drug candidates. Eloxx Pharmaceuticals is building a pipeline of molecules designed for an array of genetic diseases caused by nonsense mutations.
In June 2017, Eloxx Pharmaceuticals reverse-merged with Sevion Therapeutics Inc. This acquisition transitioned Eloxx from a private to a publicly traded company.
Funding history · 2 rounds · $98.5M total
Q&A
- What is Eloxx Pharmaceuticals' primary focus?
- Eloxx Pharmaceuticals focuses on the discovery, development, and commercialization of compounds for the treatment of rare genetic diseases, including cystic fibrosis, Duchenne muscular dystrophy, and Usher syndrome.
- When was Eloxx Pharmaceuticals founded?
- Eloxx Pharmaceuticals was founded in September 2013.
- What is the current employee count for Eloxx Pharmaceuticals?
- Eloxx Pharmaceuticals has 11-50 employees.
- What was a significant event in Eloxx Pharmaceuticals' transition to a public company?
- In June 2017, Eloxx Pharmaceuticals reverse-merged with Sevion Therapeutics Inc., which transitioned Eloxx from a private to a publicly traded company.
- What is Eloxx Pharmaceuticals' current status?
- Eloxx Pharmaceuticals is an active public company on NASDAQ as of April 2018.
- Which investors participated in Eloxx Pharmaceuticals' August 2017 funding round?
- The August 2017 funding round for Eloxx Pharmaceuticals included investors such as.
- Where is Eloxx Pharmaceuticals headquartered?
- Eloxx Pharmaceuticals is headquartered in Ness Ziona, Israel, with an office in Watertown, MA, USA.
- What is the total amount of funding Eloxx Pharmaceuticals has raised to date?
- Eloxx Pharmaceuticals has raised a total of $98,500,000 USD.
Sectors & technology
Highlights
Tags
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | eloxxpharma.com |
|---|---|
| linkedin.com/company/18504171 | |
| Wikidata | wikidata.org/wiki/Q106411647 |
Identifiers & details
| Founded | 2013-9 |
|---|---|
| Employees (exact) | 12 |
| Offices | Watertown |
| Market cap | $314 |
| Status reason | Public on NASDAQ on Apr, 2018 |
| Wikidata QID | Q106411647 |
Radar intelligence
Patents
| EPO | 10 |
|---|
Web history (Wayback)
| Domain | eloxxpharma.com |
|---|
Wikidata
| QID | Q106411647 |
|---|
Certificate / subdomain footprint
| Subdomains | 11 |
|---|